Literature DB >> 7775981

Comparison of polysaccharide iron complexes used as iron supplements.

E M Coe1, L H Bowen, J A Speer, R D Bereman.   

Abstract

An oral hematinic marketed as "water soluble polysaccharide iron complex" (Vitaline Formulas) has been characterized using x-ray powder diffraction and Mössbauer spectroscopy. Another polysaccharide iron complex marketed as Niferex (Central Pharmaceuticals) has been previously studied by us and found to have a core similar to ferrihydrite, but with some long-range order of the mineral akaganéite, beta-FeOOH. The latter is seen in other ferric carbohydrate complexes synthesized by the hydrolysis of FeCl3. This commercial product, however, is very different and has a mixture of iron components including hematite (alpha-Fe2O3) magnetite (Fe3O4), goethite (alpha-FeOOH), iron metal, and a ferrous salt.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7775981     DOI: 10.1016/0162-0134(94)00039-d

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  3 in total

1.  Single-dose bioequivalence assessment of two formulations of polysaccharide iron complex capsules in healthy adult male Chinese volunteers: A sequence-randomized, double-blind, two-way crossover study.

Authors:  Yuan-Yuan Zhang; Jun-Hong Liu; Feng Su; Ying-Tao Lui; Jun-Feng Li
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

2.  Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure.

Authors:  Gregory D Lewis; Marc J Semigran; Michael M Givertz; Rajeev Malhotra; Kevin J Anstrom; Adrian F Hernandez; Monica R Shah; Eugene Braunwald
Journal:  Circ Heart Fail       Date:  2016-05       Impact factor: 8.790

Review 3.  Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners.

Authors:  Marcin Drozd; Ewa A Jankowska; Waldemar Banasiak; Piotr Ponikowski
Journal:  Am J Cardiovasc Drugs       Date:  2017-06       Impact factor: 3.571

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.